Kwality Pharmaceuticals has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company achieved its highest-ever annual revenue of ₹503 crore in FY26, reflecting a robust growth of 36% compared to ₹370 crore in the previous fiscal year. Profit After Tax (PAT) for the year stood at ₹67.34 crore, marking a significant increase of 69% year-on-year from ₹39.80 crore in FY25. The Board approved these results on May 19, 2026.

Q4 Standalone Financial Performance

For the fourth quarter of FY26, Kwality Pharmaceuticals delivered strong standalone results, with net profit rising to ₹25.29 crore compared to ₹14.50 crore in the corresponding quarter of the previous year. Quarterly revenue came in at ₹157.12 crore versus ₹115.68 crore year-on-year, reflecting continued momentum in the business. EBITDA for the quarter stood at ₹38.70 crore compared to ₹25.90 crore in the same period last year, with EBITDA margins expanding to 24.70% from 22.40% year-on-year. The following table summarizes the key Q4 standalone metrics:

Operational Performance

For the fourth quarter of FY26, the company recorded its strongest-ever quarterly revenue of ₹157.11 crore, a growth of 35.8% over the corresponding quarter last year. EBITDA margins improved to 24% in FY26, expanding by approximately 200 basis points from 22% in the previous year. This expansion was driven by an improved product mix, higher contribution from regulated and semi-regulated markets, and operating leverage benefits. PAT margins also expanded by nearly 260 basis points to 13.4% in FY26 from 10.8% in FY25.

Strategic Developments

During the year, the company successfully cleared multiple international regulatory and customer audits. Its credit rating was upgraded to BBB+ from B+ by ICRA, reflecting a strengthened financial profile. The company initiated a large-scale Bioequivalence (BE) program covering over 40 Oral Solid Dosage (OSD) molecules and accelerated investments into its biologics pipeline. Management noted that geopolitical conditions in the Middle East began normalizing from mid-April 2026, leading to stabilization in supply chains and payment realizations.

Annual Financial Highlights

The key annual financial metrics for the period are summarized below:

FY27 Guidance

Building on its record FY26 performance, Kwality Pharmaceuticals has outlined its financial projections for FY27. The company targets revenues of over ₹650 crore, EBITDA of ₹160 crore at a margin of 25%, and net profit of ₹100 crore. The company also targets doubling revenues over the next three years, with an aspirational milestone of achieving ₹1,000 crore in topline by FY29.

Future Outlook and Capex

Management provided detailed guidance for the coming years, projecting FY28 revenue between ₹800 crore and ₹850 crore with EBITDA margins of 28%, and FY29 revenue of ₹1,000 crore with 30% EBITDA margins. Oncology revenue is expected to contribute ₹300 crore to the FY29 target, with EBITDA margins for the segment averaging 32% (40% for peptide products and 25% for routine oncology). The company plans a total capex of ₹260 crore to ₹270 crore across four projects, including hormones, oncology expansion, biosimilars, and R&D. Of this, ₹46 crore was spent in FY26, with ₹90 crore planned for FY27 and ₹90 crore to ₹100 crore for FY28. The company also expects to commission Unit 6 for hormones by November 2026, targeting ₹150 crore in revenue from unregulated and semi-regulated markets before FY29.

Kwality Pharmaceuticals Ltd has presented details of its drug development pipeline and product portfolio as part of its investor presentation, covering biosimilar candidates, monoclonal antibodies, and a hormone product pipeline at varying stages of development.

Biosimilar and Monoclonal Antibody Pipeline

The company has outlined four key molecules under development, spanning biosimilars and monoclonal antibodies, with target launch timelines set between H2 CY27 and H1 CY28. The pipeline reflects a range of development stages, from early-stage research to clinical trials and proof-of-concept achievements. The following table summarises the current status of each molecule:

Erythropoietin (EPO), the company's biosimilar candidate, is the most advanced in the pipeline, currently undergoing clinical trials with a target launch in H2 CY27. Pembrolizumab, a monoclonal antibody, has achieved proof of concept and is also targeting H2 CY27. Nivolumab and Pertuzumab are at earlier stages—early development and research phase respectively—with Pertuzumab targeting a slightly later launch in H1 CY28.

Hormone Product Portfolio

Beyond its biosimilar and monoclonal antibody pipeline, Kwality Pharmaceuticals has also outlined a hormone product portfolio covering sex hormones and synthetic hormones, as well as products requiring bioequivalence (BE) studies. The portfolio spans both injectable and oral solid dosage (OSD) forms, with development at various stages of initiation and shortlisting.

The sex hormones category has more than 20 products shortlisted in injectable form, with development already initiated. The synthetic hormones segment similarly has more than 20 products shortlisted across OSD and injectable forms, with shortlisting complete. Additionally, more than 10 products requiring BE studies in OSD form have been queued in the pipeline.

Company Overview

Kwality Pharmaceuticals Ltd is headquartered at 6th Milestone, Majitha Road, Amritsar-143601, Punjab, India. Investor relations for the company are managed by Go India Advisors.